Treatment of Helicobacter Pylori Infections Using Moxifloxacin-Triple Therapy Compared to Standard Triple and Quadruple Therapies

Helicobacter pylori (H. Pylori) is one of the most common infectious human pathogens. H. could induce inflammation, that causes illnesses and disorders upper gastrointestinal which including peptic ulcer diseases, dyspepsia, gastroesophageal reflux disease gastric mucosa-associated lymphoid tissue (MALT) lymphoma. It important to use a better tolerated greatly effective eradication regimen. In this study, 75 newly diagnosed adult patients with infection were included completed they allocated into three groups different treatment regimens for eradications; Group A (25 patients) received oral standard clarithromycin-based triple therapy 14 days. B bismuth based-quadruple 10 C moxifloxacin-based The results reported in study indicated significant higher rate (84% 80%, respectively) infections compared (52%). incidence adverse effects appeared as 72%, 64% 24% group A, respectively. moxifloxacin regimen eradication, present efficacy parallel quadruple significantly clarithromycin Also more tolerable does not increase overall other used study.